Delivery-mediated exosomal therapeutics in ischemia-reperfusion injury: advances, mechanisms, and future directions.
Shengzhe DingYu-Jin KimKai-Yu HuangDaniel UmYoungmee JungShengzhe DingPublished in: Nano convergence (2024)
Ischemia-reperfusion injury (IRI) poses significant challenges across various organ systems, including the heart, brain, and kidneys. Exosomes have shown great potentials and applications in mitigating IRI-induced cell and tissue damage through modulating inflammatory responses, enhancing angiogenesis, and promoting tissue repair. Despite these advances, a more systematic understanding of exosomes from different sources and their biotransport is critical for optimizing therapeutic efficacy and accelerating the clinical adoption of exosomes for IRI therapies. Therefore, this review article overviews the administration routes of exosomes from different sources, such as mesenchymal stem cells and other somatic cells, in the context of IRI treatment. Furthermore, this article covers how the delivered exosomes modulate molecular pathways of recipient cells, aiding in the prevention of cell death and the promotions of regeneration in IRI models. In the end, this article discusses the ongoing research efforts and propose future research directions of exosome-based therapies.
Keyphrases
- mesenchymal stem cells
- ischemia reperfusion injury
- stem cells
- umbilical cord
- cell cycle arrest
- induced apoptosis
- cell death
- oxidative stress
- cell therapy
- bone marrow
- drinking water
- signaling pathway
- heart failure
- current status
- diabetic rats
- single cell
- endothelial cells
- small molecule
- high glucose
- gene expression
- electronic health record
- vascular endothelial growth factor
- dna methylation
- genome wide